Drug
Tak 881
Tak 881: highest development phase Phase 3, developed by Takeda. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-881 NCT06747351 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) |
| TAK-881 NCT05059977 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Tak 881 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.